Clinical trial Recruiting at 3 sites Phase 3 Interventional Ages 18 to 100

Romiplostim plus prednisone vs prednisone alone in adults with newly diagnosed ITP

Official title: A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP).

Run by Amgen · NCT07700238 · Data updated 2026-11-12

This phase 3 trial tests whether adding romiplostim to prednisone helps adults with newly diagnosed primary ITP respond better than prednisone alone.

More Immune Thrombocytopenia trials Research outlook What's coming for Immune thrombocytopenia: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 100 Years
SexAll
Enrollment126 (estimated)
SponsorAmgen
Industry-sponsored
Locations3 sites (Long Beach, California and 2 other locations)
StatusRecruiting
StartedAugust 21, 2026
Main results expectedSeptember 14, 2029
Study endsOctober 14, 2029
Registry record updatedSeptember 17, 2026
Trial IDNCT07700238 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older with newly diagnosed primary ITP and platelets below 30 or below 50 with significant bleeding, not yet treated before.

Probably not a fit

Patients with life-threatening bleeding at randomization or those with contraindications to prednisone or romiplostim may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with primary ITP who have not yet been treated will be randomized to receive romiplostim in addition to prednisone or prednisone alone. The study aims to measure treatment response and safety over time, using standard platelet thresholds to guide treatment decisions. Exclusion criteria include life-threatening bleeding at randomization and prior emergency use of TPO-RAs or splenectomy. Enrollment requires a confirmed diagnosis of primary ITP by excluding other causes and a low platelet count with bleeding risk. The trial is sponsored by Amgen and conducted at a few selected U.S. centers.

Why it matters

Potential benefit: If successful, the combination could improve platelet restoration and reduce bleeding risk in newly diagnosed adult ITP patients.

How similar studies have gone: Prior studies in ITP have explored TPO-RAs with steroids, showing potential benefit, though this specific combination in untreated adults is being evaluated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years or adult legal age within country if older than 18 years.
* Diagnosis of primary ITP according to the 2019 International Consensus (ICR) that is previously untreated and requires treatment.

  * Note: The investigator should ensure that the diagnosis of primary ITP is established by excluding other causes of isolated thrombocytopenia, as outlined in the 2019 ICR, which states that the diagnosis of primary ITP is principally based on the exclusion of other causes of isolated thrombocytopenia.
  * Note: If emergency treatment is necessary, platelet count performed before emergency can be used for study inclusion.
  * Note: Emergency ITP treatment with any thrombopoietin receptor agonists (TPO-RAs), or splenectomy is not allowed.
* Platelet count \< 30 × 10\^9/L or Platelet count \< 50× 10\^9/L with clinically significant bleeding before any medical intervention.

Exclusion Criteria:

* Life-threatening bleeding at randomization.
* Known sensitivity or intolerance to any of the products to be administered during study (eg, uncontrolled diabetes) or to any Escherichia coli-derived product (eg, filgrastim, pegfilgrastim, certain insulins).
* Uncontrolled hypertension before randomization.
* Abnormal hepatic or renal function at screening.
* History of total splenectomy.
* Use of concurrent anticoagulation therapy and/or antiplatelet therapy.
* Need for nonsteroidal anti-inflammatory drugs (NSAIDs) use and use of NSAIDs within 7 days before randomization.
* Venous or arterial thrombotic event within 3 or 6 months, respectively, before randomization.
* Other protocol-defined Inclusion/Exclusion may apply.

Where it's running

  • MemorialCare Long Beach Medical Center
    Long Beach, California, United States
    Recruiting
  • The Bleeding and Clotting Disorders Institute
    Peoria, Illinois, United States
    Recruiting
  • Hematology Oncology Associates of Fredericksburg
    Fredericksburg, Virginia, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.